Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Explore how glide paths and passive retirement options work, including risk and cost differences. This intro helps you compare pros and cons before choosing a strategy.
26,696 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Five major loan-channel partnerships in five days are redefining how borrowers learn about and secure loans. The rapi...
Salesforce faces leadership questions as founder Marc Benioff approaches three decades at the helm. The company is st...
Rigetti’s towering market value vs. tiny revenue draws scrutiny as major players like Alphabet and IonQ emerge as sma...
Citi raises AMD's price target to $460 on a $132B CPU forecast through 2030, but keeps a Neutral rating, signaling th...
As tax policy and markets evolve, the math that makes these dividend stocks tax-smart remains a compelling lever for ...
Bitcoin stalls near $77K as AI-focused Worldcoin jumps 25% in a single session, highlighting a split in crypto market...
Adobe faces a pivotal shift as its own AI tool accelerates cannibalization of the stock library, forcing a rethinking...
A distressed retailer trading under $15 is drawing new attention as improving cash flow and debt reduction point to a...
XRP breached the $1 support, prompting a renewed look at downside risk and potential relief rallies. This article map...
Lilly stock jumps after Phase 3 readout for a next-generation weight-loss drug exceeded expectations. Investors see d...
SoFi Technologies has dropped about 42% over the last six months, trading near $16 as market conditions tighten. Anal...